Table 2.
Demographic distribution and disease characteristics of MS cohort (n = 519).
| Age at Study Entry (years) | 42.7 ± 9.7, 42.2 (35.5 to 50.4) | |
|---|---|---|
| Sex | Female | 364 (70.13%) |
| Male | 155 (29.87%) | |
| Age of Clinical Onset (years) | 33.5 ± 9.1, 33 (27 to 40) | |
| Disease Type | CIS | 90 (17.34%) |
| RRMS | 391 (75.34%) | |
| SPMS | 38 (7.32%) | |
| History of DMT Use at Study Entry | Never Used | 212 (40.85%) |
| Ever Used | 307 (59.15%) | |
| DMT Exposure (years) | 2.5 ± 2.5, 1.8 (0.6 to 3.5) | |
| T2 White Matter Lesion Volume (mm3) | 4636.9 ± 5775.2, 2589.4 (991.5 to 6133.2) | |
| Normalized Thalamic Volume at Study Entry (thalamic volume/ICV*1000) | 9.3 ± 1, 9.3 (8.7 to 9.9) |
CIS clinically isolated syndrome, DMT disease-modifying therapy, ICV intracranial volume, RRMS relapsing remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis, T2 T2-weighted MRI.
*Mean ± SD, Median (Q1, Q3).